You are here: Industry Insights > Sangamo

News List

Pfizer, Sangamo announce updated results of phase 1/2 Alta study of giroctocogene fitelparvovec pharmaceutical-business-review
December 09, 2020
Pfizer and Sangamo Therapeutics, a genomic medicines company, announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A.
Novartis partners with Sangamo on genomic therapies pharmaceutical-technology
August 03, 2020
Novartis has signed an exclusive, global licensing collaboration agreement with Sangamo Therapeutics to develop and commercialise genomic therapies for neurodevelopmental disorders, including autism.
Sangamo, Novartis Partner to Develop Gene Therapies for Autism contractpharma
July 31, 2020
Sangamo will receive $75M upfront and is eligible to receive up to $720M in potential milestones for three neurodevelopmental targets.
Biogen, Sangamo team up on neurological diseases pharmatimes
March 06, 2020
Biogen and Sangamo have unveiled plans to collaborate on a new global licensing agreement to develop and commercialise ST-501 for tauopathies including Alzheimer’s disease, and other neurological diseases.
Biogen and Sangamo to develop neurological disease drugs pharmaceutical-technology
March 03, 2020
Biogen and Sangamo Therapeutics have signed a global licensing agreement for the development of drugs to treat neurological diseases, including Alzheimer’s and Parkinson’s diseases.
Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 americanpharmaceuticalreview
December 24, 2019
Sangamo Therapeutics announced the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy Investigational New Drug application (IND).
Sangamo Announces Executive VP, General Counsel Appointment americanpharmaceuticalreview
August 01, 2019
Sangamo Therapeutics announced the appointment of Gary H. Loeb as Executive Vice President and General Counsel, effective immediately. Loeb will oversee all legal matters for Sangamo and will report to the Chief Executive Officer.
Sangamo announces promising early results for haemophilia A gene therapy pharmaceutical-technology
April 23, 2019
Sangamo announces promising early results for haemophilia A gene therapy.
Sangamo, Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy americanpharmaceuticalreview
April 11, 2019
Sangamo, Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy.
Pfizer, Sangamo report positive early-stage data for gene therapy SB-525 in haemophilia A firstwordpharma
April 02, 2019
Pfizer and Sangamo Therapeutics on Tuesday reported that two patients with severe haemophilia A……

Previous page 1 2 Next page